Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

11.8K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
11.8K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.3K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

2.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.0K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

A plant vesicle-dendritic cell chimera for enhancing cancer immunotherapy.

Nature communications·2026
Same author

The role of pterostilbene in alleviating inflammatory response and pyroptosis in myocardial ischemia-reperfusion by inhibiting the cGAS-STING pathway.

Cytotechnology·2026
Same author

The Last Mile Problem: A Critical Assessment of Physics-Based and AI Tools for Small Molecule Binding Prediction in Virtual Screening.

Journal of chemical information and modeling·2026
Same author

Prognostic value of the CT-based Suidan scoring system in advanced epithelial ovarian cancer.

Frontiers in oncology·2026
Same author

In Reply: Comment on "Nonsurgical Integrative Treatments for Degenerative Symptomatic Lumbar Spondylolisthesis".

Mayo Clinic proceedings·2026
Same author

Discovery of Small-Molecule Antagonists of PHF1 and 19 Demonstrates the Ligandability of PRC2 Accessory Proteins.

ACS bio & med chem Au·2026

相关实验视频

Updated: May 14, 2025

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

7.9K

发现了新的TYRO3/MERTK双抑制剂.

Deyu Kong1, Jichen Zhao1, Daowei Huang1

  • 1Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.

Journal of medicinal chemistry
|April 11, 2025
PubMed
概括

研究人员发现了UNC9435,这是第一个针对TYRO3和MERTK受体氨酸激酶的强有力的双重抑制剂. 这种新化合物对治疗依赖于这些特定致癌途径的癌症具有前途.

更多相关视频

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.8K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.1K

相关实验视频

Last Updated: May 14, 2025

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

7.9K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.8K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.1K

科学领域:

  • 生物化学 生物化学
  • 分子生物学分子生物学
  • 在瘤学瘤学.

背景情况:

  • TAM受体氨酸激酶家族 (TYRO3,AXL,MERTK) 在瘤发生和天生的免疫力中发挥着关键作用.
  • TAM家族成员的不同表达和功能需要特定于背景的治疗策略.
  • 针对协调的TYRO3和MERTK行动可能在某些疾病和瘤中提供治疗优势.

研究的目的:

  • 发现和描述TYRO3和MERTK的第一个强大的双重抑制剂.
  • 评估新型抑制剂对癌症相关标和途径的选择性和有效性.

主要方法:

  • 发现了UNC9435,一种新的小分子抑制剂.
  • 生物化学测试 (纳米BRET) 来确定酶抑制和选择性.
  • 基于细胞的测试,以评估下游信号和细胞效应 (殖民地形成) 的抑制.

主要成果:

  • UNC9435是第一个被发现的TYRO3和MERTK的强有力的双重抑制剂.
  • 该化合物对MERTK对AXL和FLT3具有很高的选择性,对其他激酶具有广泛的选择性.
  • UNC9435有效地抑制癌细胞中的TYRO3和MERTK信号传递,并减少非小细胞肺癌殖民地形成.

结论:

  • UNC9435代表了对依赖TYRO3和MERTK信号传递的癌症的有前途的新型治疗候选药物.
  • 针对TYRO3和MERTK的双重抑制策略需要进一步研究癌症治疗.